Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 145 to 156 of 156 entries
Sorted by: Best Match Show Resources per page
A new diet supplement formulation containing cranberry extract for the treatment of feline idiopathic cystitis.

Natural product research

Colombino E, Cavana P, Martello E, Devalle V, Miniscalco B, Ravera N, Zanatta R, Capucchio MT, Biasibetti E.
PMID: 34039227
Nat Prod Res. 2021 May 27;1-4. doi: 10.1080/14786419.2021.1925273. Epub 2021 May 27.

This study aimed to investigate whether cranberry extract could reduce lower urinary tract (LUT) and gastro-intestinal (GI) signs in feline idiopathic cystitis (FIC). Twenty-one client-owned cats were randomly allocated to two groups: a treated group (T, n = 10)...

Cite
Colombino E, Cavana P, Martello E, et al. A new diet supplement formulation containing cranberry extract for the treatment of feline idiopathic cystitis. Nat Prod Res. 2021;1-4doi: 10.1080/14786419.2021.1925273.
Colombino, E., Cavana, P., Martello, E., Devalle, V., Miniscalco, B., Ravera, N., Zanatta, R., Capucchio, M. T., & Biasibetti, E. (2021). A new diet supplement formulation containing cranberry extract for the treatment of feline idiopathic cystitis. Natural product research, 1-4. https://doi.org/10.1080/14786419.2021.1925273
Colombino, Elena, et al. "A new diet supplement formulation containing cranberry extract for the treatment of feline idiopathic cystitis." Natural product research vol. (2021): 1-4. doi: https://doi.org/10.1080/14786419.2021.1925273
Colombino E, Cavana P, Martello E, Devalle V, Miniscalco B, Ravera N, Zanatta R, Capucchio MT, Biasibetti E. A new diet supplement formulation containing cranberry extract for the treatment of feline idiopathic cystitis. Nat Prod Res. 2021 May 27;1-4. doi: 10.1080/14786419.2021.1925273. Epub 2021 May 27. PMID: 34039227.
Copy Download .nbib Format: NLM
Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation

Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, Mukai H.
PMID: 34982354
Qual Life Res. 2022 Jan 04; doi: 10.1007/s11136-021-03074-y. Epub 2022 Jan 04.

PURPOSE: To establish minimal important differences (MIDs) for the European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 (EORTC QLQ-C30) in patients with metastatic breast cancer.METHODS: The dataset was obtained from the SELECT BC-CONFIRM...

Cite
Kawahara T, Taira N, Shiroiwa T, et al. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. Qual Life Res. 2022;doi: 10.1007/s11136-021-03074-y.
Kawahara, T., Taira, N., Shiroiwa, T., Hagiwara, Y., Fukuda, T., Uemura, Y., & Mukai, H. (2022). Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, . https://doi.org/10.1007/s11136-021-03074-y
Kawahara, Takuya, et al. "Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial." Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation vol. (2022). doi: https://doi.org/10.1007/s11136-021-03074-y
Kawahara T, Taira N, Shiroiwa T, Hagiwara Y, Fukuda T, Uemura Y, Mukai H. Minimal important differences of EORTC QLQ-C30 for metastatic breast cancer patients: Results from a randomized clinical trial. Qual Life Res. 2022 Jan 04; doi: 10.1007/s11136-021-03074-y. Epub 2022 Jan 04. PMID: 34982354.
Copy Download .nbib Format: NLM
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.

International journal of molecular sciences

Fujihara M, Shien T, Shien K, Suzawa K, Takeda T, Zhu Y, Mamori T, Otani Y, Yoshioka R, Uno M, Suzuki Y, Abe Y, Hatono M, Tsukioki T, Takahashi Y, Kochi M, Iwamoto T, Taira N, Doihara H, Toyooka S.
PMID: 34884609
Int J Mol Sci. 2021 Nov 26;22(23). doi: 10.3390/ijms222312809.

Trastuzumab-emtansine (T-DM1) is a therapeutic agent molecularly targeting human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC), and it is especially effective for MBC with resistance to trastuzumab. Although several reports have described T-DM1 resistance, few have...

Cite
Fujihara M, Shien T, Shien K, et al. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. Int J Mol Sci. 2021;22(23)doi: 10.3390/ijms222312809.
Fujihara, M., Shien, T., Shien, K., Suzawa, K., Takeda, T., Zhu, Y., Mamori, T., Otani, Y., Yoshioka, R., Uno, M., Suzuki, Y., Abe, Y., Hatono, M., Tsukioki, T., Takahashi, Y., Kochi, M., Iwamoto, T., Taira, N., Doihara, H., & Toyooka, S. (2021). YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. International journal of molecular sciences, 22(23), . https://doi.org/10.3390/ijms222312809
Fujihara, Miwa, et al. "YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development." International journal of molecular sciences vol. 22,23 (2021). doi: https://doi.org/10.3390/ijms222312809
Fujihara M, Shien T, Shien K, Suzawa K, Takeda T, Zhu Y, Mamori T, Otani Y, Yoshioka R, Uno M, Suzuki Y, Abe Y, Hatono M, Tsukioki T, Takahashi Y, Kochi M, Iwamoto T, Taira N, Doihara H, Toyooka S. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development. Int J Mol Sci. 2021 Nov 26;22(23). doi: 10.3390/ijms222312809. PMID: 34884609; PMCID: PMC8657782.
Copy Download .nbib Format: NLM
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.

Cancer letters

Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R.
PMID: 34971753
Cancer Lett. 2021 Dec 28;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28.

Myeloid-derived suppressor cells (MDSCs) play a major role in cancer progression. In this study, we investigated the mechanisms by which complement C5a increases the capacity of polymorphonuclear MDSCs (PMN-MDSCs) to promote tumor growth and metastatic spread. Stimulation of PMN-MDSCs...

Cite
Ortiz-Espinosa S, Morales X, Senent Y, et al. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Lett. 2021;529:70-84doi: 10.1016/j.canlet.2021.12.027.
Ortiz-Espinosa, S., Morales, X., Senent, Y., Alignani, D., Tavira, B., Macaya, I., Ruiz, B., Moreno, H., Remírez, A., Sainz, C., Rodriguez-Pena, A., Oyarbide, A., Ariz, M., Andueza, M. P., Valencia, K., Teijeira, A., Hoehlig, K., Vater, A., Rolfe, B., Woodruff, T. M., Lopez-Picazo, J. M., Vicent, S., Kochan, G., Escors, D., Gil-Bazo, I., Perez-Gracia, J. L., Montuenga, L. M., Lambris, J. D., Ortiz de Solorzano, C., Lecanda, F., Ajona, D., & Pio, R. (2021). Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer letters, 52970-84. https://doi.org/10.1016/j.canlet.2021.12.027
Ortiz-Espinosa, Sergio, et al. "Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis." Cancer letters vol. 529 (2021): 70-84. doi: https://doi.org/10.1016/j.canlet.2021.12.027
Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Lett. 2021 Dec 28;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28. PMID: 34971753.
Copy Download .nbib Format: NLM
Effect of high .

The European respiratory journal

Taboada M, Rodríguez N, Varela PM, Rodríguez MT, Abelleira R, González A, Casal A, Díaz Peromingo JA, Lama A, Domínguez MJ, Rábade C, Páez EM, Riveiro V, Pernas H, Del Carmen Beceiro M, Caruezo V, Naveira A, Cariñena A, Cabaleiro T, Estany-Gestal A, Zarra I, Pose A, Valdés L, Álvarez-Escudero J.
PMID: 34916266
Eur Respir J. 2021 Dec 16; doi: 10.1183/13993003.02518-2021. Epub 2021 Dec 16.

BACKGROUND: Low dose dexamethasone demonstrated clinical improvement in patients with coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the efficacy of high dose of dexamethasone is limited.METHODS: We performed a randomised, open-label, controlled trial involving hospitalised patients...

Cite
Taboada M, Rodríguez N, Varela PM, et al. Effect of high . Eur Respir J. 2021;doi: 10.1183/13993003.02518-2021.
Taboada, M., Rodríguez, N., Varela, P. M., Rodríguez, M. T., Abelleira, R., González, A., Casal, A., Díaz Peromingo, J. A., Lama, A., Domínguez, M. J., Rábade, C., Páez, E. M., Riveiro, V., Pernas, H., Del Carmen Beceiro, M., Caruezo, V., Naveira, A., Cariñena, A., Cabaleiro, T., Estany-Gestal, A., Zarra, I., Pose, A., Valdés, L., & Álvarez-Escudero, J. (2021). Effect of high . The European respiratory journal, . https://doi.org/10.1183/13993003.02518-2021
Taboada, Manuel, et al. "Effect of high ." The European respiratory journal vol. (2021). doi: https://doi.org/10.1183/13993003.02518-2021
Taboada M, Rodríguez N, Varela PM, Rodríguez MT, Abelleira R, González A, Casal A, Díaz Peromingo JA, Lama A, Domínguez MJ, Rábade C, Páez EM, Riveiro V, Pernas H, Del Carmen Beceiro M, Caruezo V, Naveira A, Cariñena A, Cabaleiro T, Estany-Gestal A, Zarra I, Pose A, Valdés L, Álvarez-Escudero J. Effect of high . Eur Respir J. 2021 Dec 16; doi: 10.1183/13993003.02518-2021. Epub 2021 Dec 16. PMID: 34916266; PMCID: PMC8678498.
Copy Download .nbib Format: NLM
Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus.

Oncogene

Miller AK, Tavera G, Dominguez RL, Camargo MC, Waterboer T, Wilson KT, Williams SM, Morgan DR.
PMID: 34376808
Oncogene. 2021 Oct;40(40):5963-5969. doi: 10.1038/s41388-021-01981-5. Epub 2021 Aug 10.

The primary cause of gastric cancer is chronic infection with Helicobacter pylori (H. pylori), particularly the high-risk genotype cagA, and risk modification by human genetic variants. We studied 94 variants in 54 genes for association with gastric cancer, including...

Cite
Miller AK, Tavera G, Dominguez RL, et al. Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus. Oncogene. 2021;40(40):5963-5969doi: 10.1038/s41388-021-01981-5.
Miller, A. K., Tavera, G., Dominguez, R. L., Camargo, M. C., Waterboer, T., Wilson, K. T., Williams, S. M., & Morgan, D. R. (2021). Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus. Oncogene, 40(40), 5963-5969. https://doi.org/10.1038/s41388-021-01981-5
Miller, Anna K, et al. "Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus." Oncogene vol. 40,40 (2021): 5963-5969. doi: https://doi.org/10.1038/s41388-021-01981-5
Miller AK, Tavera G, Dominguez RL, Camargo MC, Waterboer T, Wilson KT, Williams SM, Morgan DR. Ornithine decarboxylase (ODC1) gene variant (rs2302615) is associated with gastric cancer independently of Helicobacter pylori CagA serostatus. Oncogene. 2021 Oct;40(40):5963-5969. doi: 10.1038/s41388-021-01981-5. Epub 2021 Aug 10. PMID: 34376808; PMCID: PMC8692072.
Copy Download .nbib Format: NLM
Effect of high .

The European respiratory journal

Taboada M, Rodríguez N, Varela PM, Rodríguez MT, Abelleira R, González A, Casal A, Díaz Peromingo JA, Lama A, Domínguez MJ, Rábade C, Páez EM, Riveiro V, Pernas H, Del Carmen Beceiro M, Caruezo V, Naveira A, Cariñena A, Cabaleiro T, Estany-Gestal A, Zarra I, Pose A, Valdés L, Álvarez-Escudero J.
PMID: 34916266
Eur Respir J. 2021 Dec 16; doi: 10.1183/13993003.02518-2021. Epub 2021 Dec 16.

BACKGROUND: Low dose dexamethasone demonstrated clinical improvement in patients with coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the efficacy of high dose of dexamethasone is limited.METHODS: We performed a randomised, open-label, controlled trial involving hospitalised patients...

Cite
Taboada M, Rodríguez N, Varela PM, et al. Effect of high . Eur Respir J. 2021;doi: 10.1183/13993003.02518-2021.
Taboada, M., Rodríguez, N., Varela, P. M., Rodríguez, M. T., Abelleira, R., González, A., Casal, A., Díaz Peromingo, J. A., Lama, A., Domínguez, M. J., Rábade, C., Páez, E. M., Riveiro, V., Pernas, H., Del Carmen Beceiro, M., Caruezo, V., Naveira, A., Cariñena, A., Cabaleiro, T., Estany-Gestal, A., Zarra, I., Pose, A., Valdés, L., & Álvarez-Escudero, J. (2021). Effect of high . The European respiratory journal, . https://doi.org/10.1183/13993003.02518-2021
Taboada, Manuel, et al. "Effect of high ." The European respiratory journal vol. (2021). doi: https://doi.org/10.1183/13993003.02518-2021
Taboada M, Rodríguez N, Varela PM, Rodríguez MT, Abelleira R, González A, Casal A, Díaz Peromingo JA, Lama A, Domínguez MJ, Rábade C, Páez EM, Riveiro V, Pernas H, Del Carmen Beceiro M, Caruezo V, Naveira A, Cariñena A, Cabaleiro T, Estany-Gestal A, Zarra I, Pose A, Valdés L, Álvarez-Escudero J. Effect of high . Eur Respir J. 2021 Dec 16; doi: 10.1183/13993003.02518-2021. Epub 2021 Dec 16. PMID: 34916266.
Copy Download .nbib Format: NLM
Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration.

Drug delivery and translational research

Alves GL, Teixeira FV, da Rocha PBR, Krawczyk-Santos AP, Andrade LM, Cunha-Filho M, Marreto RN, Taveira SF.
PMID: 33682031
Drug Deliv Transl Res. 2021 Mar 07; doi: 10.1007/s13346-021-00949-y. Epub 2021 Mar 07.

Transdermal administration of raloxifene hydrochloride (RLX)-loaded nanostructured lipid carriers (NLCs) has been proposed to circumvent its low oral bioavailability (2%). Preformulation studies were carried out to evaluate drug-excipient compatibility of various adjuvants commonly used for NLC preparation (waxes, cholesterol,...

Cite
Alves GL, Teixeira FV, da Rocha PBR, et al. Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration. Drug Deliv Transl Res. 2021;doi: 10.1007/s13346-021-00949-y.
Alves, G. L., Teixeira, F. V., da Rocha, P. B. R., Krawczyk-Santos, A. P., Andrade, L. M., Cunha-Filho, M., Marreto, R. N., & Taveira, S. F. (2021). Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration. Drug delivery and translational research, . https://doi.org/10.1007/s13346-021-00949-y
Alves, Guilherme L, et al. "Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration." Drug delivery and translational research vol. (2021). doi: https://doi.org/10.1007/s13346-021-00949-y
Alves GL, Teixeira FV, da Rocha PBR, Krawczyk-Santos AP, Andrade LM, Cunha-Filho M, Marreto RN, Taveira SF. Preformulation and characterization of raloxifene-loaded lipid nanoparticles for transdermal administration. Drug Deliv Transl Res. 2021 Mar 07; doi: 10.1007/s13346-021-00949-y. Epub 2021 Mar 07. PMID: 33682031.
Copy Download .nbib Format: NLM
Rapid formation of mature microbialites in Lake Alchichica, Mexico.

Environmental microbiology reports

Iniesto M, Moreira D, Benzerara K, Muller E, Bertolino P, Tavera R, López-García P.
PMID: 34396701
Environ Microbiol Rep. 2021 Oct;13(5):600-605. doi: 10.1111/1758-2229.12957. Epub 2021 Aug 15.

Microbialites are emblematic sedimentary rocks formed by phylogenetically and metabolically complex microbial communities thriving under specific physicochemical conditions. Most microbialites are photosynthesis-based ecosystems frequently formed by carbonates, thereby capturing inorganic carbon in the form of both, organic matter and...

Cite
Iniesto M, Moreira D, Benzerara K, et al. Rapid formation of mature microbialites in Lake Alchichica, Mexico. Environ Microbiol Rep. 2021;13(5):600-605doi: 10.1111/1758-2229.12957.
Iniesto, M., Moreira, D., Benzerara, K., Muller, E., Bertolino, P., Tavera, R., & López-García, P. (2021). Rapid formation of mature microbialites in Lake Alchichica, Mexico. Environmental microbiology reports, 13(5), 600-605. https://doi.org/10.1111/1758-2229.12957
Iniesto, Miguel, et al. "Rapid formation of mature microbialites in Lake Alchichica, Mexico." Environmental microbiology reports vol. 13,5 (2021): 600-605. doi: https://doi.org/10.1111/1758-2229.12957
Iniesto M, Moreira D, Benzerara K, Muller E, Bertolino P, Tavera R, López-García P. Rapid formation of mature microbialites in Lake Alchichica, Mexico. Environ Microbiol Rep. 2021 Oct;13(5):600-605. doi: 10.1111/1758-2229.12957. Epub 2021 Aug 15. PMID: 34396701.
Copy Download .nbib Format: NLM
Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis.

Diagnostics (Basel, Switzerland)

Moreira VM, Mascarenhas P, Machado V, Botelho J, Mendes JJ, Taveira N, Almeida MG.
PMID: 33670020
Diagnostics (Basel). 2021 Feb 21;11(2). doi: 10.3390/diagnostics11020363.

The rapid and accurate testing of SARS-CoV-2 infection is still crucial to mitigate, and eventually halt, the spread of this disease. Currently, nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) are the recommended standard sampling techniques, yet, these have some...

Cite
Moreira VM, Mascarenhas P, Machado V, et al. Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2021;11(2)doi: 10.3390/diagnostics11020363.
Moreira, V. M., Mascarenhas, P., Machado, V., Botelho, J., Mendes, J. J., Taveira, N., & Almeida, M. G. (2021). Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis. Diagnostics (Basel, Switzerland), 11(2), . https://doi.org/10.3390/diagnostics11020363
Moreira, Vânia M, et al. "Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis." Diagnostics (Basel, Switzerland) vol. 11,2 (2021). doi: https://doi.org/10.3390/diagnostics11020363
Moreira VM, Mascarenhas P, Machado V, Botelho J, Mendes JJ, Taveira N, Almeida MG. Diagnosis of SARS-Cov-2 Infection by RT-PCR Using Specimens Other Than Naso- and Oropharyngeal Swabs: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2021 Feb 21;11(2). doi: 10.3390/diagnostics11020363. PMID: 33670020; PMCID: PMC7926389.
Copy Download .nbib Format: NLM
Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis.

Cancer letters

Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R.
PMID: 34971753
Cancer Lett. 2021 Dec 28;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28.

Myeloid-derived suppressor cells (MDSCs) play a major role in cancer progression. In this study, we investigated the mechanisms by which complement C5a increases the capacity of polymorphonuclear MDSCs (PMN-MDSCs) to promote tumor growth and metastatic spread. Stimulation of PMN-MDSCs...

Cite
Ortiz-Espinosa S, Morales X, Senent Y, et al. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Lett. 2021;529:70-84doi: 10.1016/j.canlet.2021.12.027.
Ortiz-Espinosa, S., Morales, X., Senent, Y., Alignani, D., Tavira, B., Macaya, I., Ruiz, B., Moreno, H., Remírez, A., Sainz, C., Rodriguez-Pena, A., Oyarbide, A., Ariz, M., Andueza, M. P., Valencia, K., Teijeira, A., Hoehlig, K., Vater, A., Rolfe, B., Woodruff, T. M., Lopez-Picazo, J. M., Vicent, S., Kochan, G., Escors, D., Gil-Bazo, I., Perez-Gracia, J. L., Montuenga, L. M., Lambris, J. D., Ortiz de Solorzano, C., Lecanda, F., Ajona, D., & Pio, R. (2021). Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer letters, 52970-84. https://doi.org/10.1016/j.canlet.2021.12.027
Ortiz-Espinosa, Sergio, et al. "Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis." Cancer letters vol. 529 (2021): 70-84. doi: https://doi.org/10.1016/j.canlet.2021.12.027
Ortiz-Espinosa S, Morales X, Senent Y, Alignani D, Tavira B, Macaya I, Ruiz B, Moreno H, Remírez A, Sainz C, Rodriguez-Pena A, Oyarbide A, Ariz M, Andueza MP, Valencia K, Teijeira A, Hoehlig K, Vater A, Rolfe B, Woodruff TM, Lopez-Picazo JM, Vicent S, Kochan G, Escors D, Gil-Bazo I, Perez-Gracia JL, Montuenga LM, Lambris JD, Ortiz de Solorzano C, Lecanda F, Ajona D, Pio R. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Lett. 2021 Dec 28;529:70-84. doi: 10.1016/j.canlet.2021.12.027. Epub 2021 Dec 28. PMID: 34971753.
Copy Download .nbib Format: NLM
Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail?.

Medical decision making : an international journal of the Society for Medical Decision Making

Shiroiwa T, Hagiwara Y, Taira N, Kawahara T, Konomura K, Iwamoto T, Noto S, Fukuda T, Shimozuma K.
PMID: 33899589
Med Decis Making. 2022 Jan;42(1):60-67. doi: 10.1177/0272989X211010171. Epub 2021 Apr 24.

PURPOSE: This study aimed to determine whether continual electronic patient-reported outcome (ePRO) measurements at home can capture the fluctuations in health-related quality of life (HRQOL) scores between visits.METHODS: We performed a randomized controlled trial to compare the scores obtained...

Cite
Shiroiwa T, Hagiwara Y, Taira N, et al. Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail?. Med Decis Making. 2021;42(1):60-67doi: 10.1177/0272989X211010171.
Shiroiwa, T., Hagiwara, Y., Taira, N., Kawahara, T., Konomura, K., Iwamoto, T., Noto, S., Fukuda, T., & Shimozuma, K. (2022). Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail?. Medical decision making : an international journal of the Society for Medical Decision Making, 42(1), 60-67. https://doi.org/10.1177/0272989X211010171
Shiroiwa, Takeru, et al. "Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail?." Medical decision making : an international journal of the Society for Medical Decision Making vol. 42,1 (2022): 60-67. doi: https://doi.org/10.1177/0272989X211010171
Shiroiwa T, Hagiwara Y, Taira N, Kawahara T, Konomura K, Iwamoto T, Noto S, Fukuda T, Shimozuma K. Randomized Controlled Trial of Paper-Based at a Hospital versus Continual Electronic Patient-Reported Outcomes at Home for Metastatic Cancer Patients: Does Electronic Measurement at Home Detect Patients' Health Status in Greater Detail?. Med Decis Making. 2022 Jan;42(1):60-67. doi: 10.1177/0272989X211010171. Epub 2021 Apr 24. PMID: 33899589.
Copy Download .nbib Format: NLM
Showing 145 to 156 of 156 entries